Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KMV002 in Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer
NCT07866300Phase 1Not yet recruiting
- Sponsor
- Chimivac
- Start
- Nov 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of KMV002 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Chimivac. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
KMV002
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07866300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866300.